…LDL particles from the circulation. Statins also reduce production of apoB 100 containing lipoproteins and exert effects beyond LDL C reduction, including modulation of inflammation…

Cardiology Clinical chemistry & laboratory medicine Definition and structure Lipoprotein(a), abbreviated Lp(a), is an LDL like circulating lipoprotein particle. It contains one molecule of…

…combined dyslipidaemia, non HDL C is particularly relevant because it captures triglyceride rich lipoproteins in addition to LDL and other apoB containing particles. Cardiovascular risk…

…a broader estimate of atherogenic cholesterol than LDL C alone. It is particularly informative when triglyceride rich lipoproteins are increased, as commonly occurs with obesity…

…rationale Bempedoic acid is an oral, small molecule lipid lowering agent used to reduce low density lipoprotein cholesterol (LDL C), particularly when statins cannot be…

…hypercholesterolaemia (FH) is an inherited disorder characterized by persistently elevated plasma low density lipoprotein cholesterol (LDL C) from early life and a consequent excess risk…

…of cholesterol delivered to the liver. The resulting hepatic response includes increased expression of low density lipoprotein receptors (LDLRs), which enhances removal of circulating LDL…

…PCSK9 synthesis decreases circulating PCSK9, increases the availability of hepatic low density lipoprotein cholesterol (LDL C) receptors at the cell surface, and thereby enhances removal…

…and acute coronary syndromes (ACS). Its principal therapeutic objective is reduction of low density lipoprotein cholesterol (LDL C), the primary lipid target in contemporary secondary…

…Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a hepatic protein that regulates the availability of the low density lipoprotein receptor (LDL receptor) on hepatocytes…